IN THE CLAIMS

Claim 1 (original): An implantable delivery system comprising, in combination: a cytotoxic agent; a high molecular weight hyaluronic acid conjugated with the cytotoxic agent to create a conjugation which is hydrophilic; and a bioresorbable delivery vehicle for the conjugation, with the bioresorbable delivery vehicle and the conjugation as a cargo being implantable to a wound under repair.

Claim 2 (original): The implantable delivery system of claim 1 further comprising, in combination: high molecular weight hyaluronic acid blended with the conjugation.

Claim 3 (original): The implantable delivery system of claim 2 with the high molecular weight hyaluronic acid blended with the conjugation by a mass ratio in the order of 1:1.

Claim 4 (original): The implantable delivery system of claim 2 further comprising, in combination: another cytotoxic agent, with the other cytotoxic agent being a passive cargo residing in the delivery vehicle for sequential delivery to the wound after the cytotoxic agent of the conjugation.

Claims 5-10 (canceled).

Claim 11 (original): An implantable delivery system comprising, in combination: a first cytotoxic agent; a second cytotoxic agent different from but complimentary to the first cytotoxic agent; a first bioresorbable delivery vehicle which is hydrophobic, with the first cytotoxic agent being a cargo in the first bioresorbable vehicle for delivery of the first cytotoxic agent during resorption of the first bioresorbable delivery vehicle, with the first bioresorbable vehicle including void spaces; a second bioresorbable delivery vehicle which is hydrophilic, with the second cytotoxic agent being a cargo in the second bioresorbable vehicle for delivery of the second cytotoxic agent during resorption of the second bioresorbable delivery vehicle, with the second bioresorbable delivery vehicle and the second cytotoxic agent located in the void spaces of the first bioresorbable delivery vehicle.

Claim 12 (original): The implantable delivery system of claim 11 with the second cytotoxic agent being chemically bound to the second bioresorbable delivery vehicle.

Claim 13 (original): The implantable delivery system of claim 12 with the second bioresorbable delivery vehicle being hyaluroric acid conjugated to the second cytotoxic agent.

Claims 14-19 (canceled).

Claim 20 (original): The implantable delivery system of claim 13 further comprising, in combination: high molecular weight hyaluronic acid blended with the conjugation.

Claim 21 (currently amended): The implantable delivery system of claim 11 with the first cytotoxic agent adapted to damage a cell's ability to accurately replicate, and with the second cytotoxic agent adapted to paralyze a cell's ~~cytoskeleton~~ **cytoskeleton**.

Claim 22 (original): An implantable delivery system comprising, in combination: cisplatin; paclitaxel; and a bioresorbable delivery device for the paclitaxel and the cisplatin, with the bioresorbable delivery device initially releasing the paclitaxel followed sequentially by releasing of the cisplatin.

Claim 23 (original): The implantable delivery system of claim 22 with the bioresorbable delivery device sequentially releasing the paclitaxel and the cisplatin initially at high level concentrations followed by a lower but sustained systematic release.

Claim 24 (original): The implantable delivery system of claim 23 with the bioresorbable delivery device including a first bioresorbable delivery vehicle, with the cisplatin being a cargo in the first bioresorbable delivery vehicle, with the first bioresorbable delivery vehicle including void spaces, with the bioresorbable delivery device further including a second bioresorbable delivery vehicle located in the void spaces of the first bioresorbable delivery device, with the paclitaxel being a cargo in the second bioresorbable delivery device.

Claim 25 (original): Cancer treatment method comprising:

implanting a bioresorbable delivery system into a wound for releasing first and second cytotoxic agents in a predetermined chronologic sequence with the first cytotoxic agent being released first followed by release of the second cytotoxic agent; and

radiating the wound during release of the second cytotoxic agent and after initial release of the first cytotoxic agent.

Claim 26 (original): The cancer treatment method of claim 25 with the first and second cytotoxic agents being each released initially at high local concentrations followed by a lower but sustained systemic release.

Claim 27 (original): The cancer treatment method of claim 26 with the first cytotoxic agent adapted to paralyze a cell's cyctoskeleton and with the second cytotoxic agent adapted to damage a cell's ability to accurately replate, with radiating the wound damaging a cell's ability to repair damaged DNA.

Claim 28 (original): The cancer treatment method of claim 26 with the first cytotoxic agent being paclitaxel and with the second cytotoxic agent being cisplatin.

Claim 29 (new): The cancer treatment method of claim 25 wherein the bioresorbable delivery system comprises a first bioresorbable delivery vehicle which is hydrophobic, with the second cytotoxic agent different from but complimentary to the first cytotoxic agent, with the first cytotoxic agent being a cargo in the first bioresorbable vehicle for delivery of the first cytotoxic agent during resorption of the first bioresorbable delivery vehicle, with the first bioresorbable vehicle including void spaces; a second bioresorbable delivery vehicle which is hydrophilic, with the second cytotoxic agent being a cargo in the second bioresorbable vehicle for delivery of the second cytotoxic agent during resorption of the second bioresorbable delivery vehicle, with the second bioresorbable delivery vehicle and the second cytotoxic agent located in the void spaces of the first bioresorbable delivery vehicle.

Claim 30 (new): The cancer treatment method of claim 29 further comprising chemically binding the second cytotoxic agent to the second bioresorbable delivery vehicle.

Claim 31 (new): The cancer treatment method of claim 30 further comprising conjugating the second bioresorbable delivery vehicle to the second cytotoxic agent.

Claim 32 (new): The cancer treatment method of claim 31 wherein the second bioresorbable delivery vehicle comprises hyaluronic acid.

Claim 33 (new): The cancer treatment method of claim 32 with the hyaluronic acid having a high molecular weight.

Claim 34 (new): The cancer treatment method of claim 31 with the second cytotoxic agent being paclitaxel.

Claim 35 (new): The cancer treatment method of claim 34 with the first cytotoxic agent being cisplatin.

Claim 36 (new): The cancer treatment method of claim 35 further comprising defining the void spaces of the first bioresorbable delivery vehicle by an internal architecture of partially enclosed, randomly sized, shaped and positioned intercommunicating interstices dictating a final three-dimensional morphology of repair tissue.

Claim 37 (new): The cancer treatment method of claim 36 with the first bioresorbable delivery vehicle being formed of a bioresorbable material selected from a group of alphahydroxy acids.

Claim 38 (new): The cancer treatment method of claim 31 further comprising blending high molecular weight hyaluronic acid with the conjugation.

Claim 39 (new): The cancer treatment method of claim 29 with the first cytotoxic agent adapted to damage a cell's ability to accurately replicate, and with the second cytotoxic agent adapted to paralyze a cell's cytoskeleton.

Claim 40 (new): Surgical method comprising:

conjugating a high molecular weight hyaluronic acid with a cytotoxic agent to create a conjugation which is hydrophilic;

providing a bioresorbable delivery vehicle for the conjugation; and

implanting the bioresorbable delivery vehicle and the conjugation as a cargo to a wound under repair.